SAS Journal of Surgery
Abbreviated Key Title: SAS J Surg
ISSN 2454-5104
Journal homepage: https://www.saspublishers.com

OPEN ACCESS

General Surgery

Comprehensive Review on Carcinoma of the Gallbladder: Epidemiology, Pathogenesis, Diagnosis, and Contemporary Management Strategies

Dr. Ijan Dhamala[1*], Dr. Soniya Bhatta[2], Dr. Nayana S Kumar[3], Dr. Gunjan Thapa[4], Dr. Pratik Sharma Gairhe[5], Dr. Ashish Mishra[6]

[1]MS, General Surgery, AIIMS Rishikesh
[2]JR, Department of Anaesthesia, AIIMS Rishikesh
[3]Assistant Professor, General Surgery, Government Medical College, Trivandrum
[4]MDS, Oral and Maxillofacial Surgery, KUSMS
[5]JR, Department of Pathology, KUSMS
[6]MS, General Surgery, AIIMS Rishikesh

DOI: https://doi.org/10.36347/sasjs.2025.v11i08.008 | **Received:** 16.06.2025 | **Accepted:** 12.08.2025 | **Published:** 16.08.2025

***Corresponding author:** Dr. Ijan Dhamala
MS, General Surgery, AIIMS Rishikesh

Abstract | **Review Article**

Carcinoma of the gallbladder (Gallbladder Cancer, GBC) is an uncommon yet highly aggressive malignancy associated with a dismal prognosis, primarily due to its asymptomatic presentation in early stages and rapid progression to advanced disease. Representing the most prevalent cancer of the biliary tract and ranking as the fifth most common gastrointestinal malignancy globally, GBC poses significant diagnostic and therapeutic challenges. This exhaustive review synthesizes current evidence on the epidemiology, etiopathogenesis, molecular mechanisms, clinical manifestations, diagnostic techniques, staging classifications, and evolving treatment paradigms for gallbladder carcinoma. Additionally, we explore novel therapeutic avenues, including immunotherapy and targeted molecular agents, while highlighting future research directions aimed at improving survival outcomes.

Keywords: gallbladder cancer, cholelithiasis, adenocarcinoma, radical cholecystectomy, immunotherapy, targeted therapy.

INTRODUCTION

Gallbladder carcinoma (GBC) is a lethal neoplasm originating from the epithelial lining of the gallbladder, characterized by late-stage diagnosis and limited therapeutic efficacy. Accounting for approximately 1.2% of all global cancer diagnoses, GBC exhibits marked geographical disparities, with endemic regions reporting alarmingly high incidence rates [1]. The insidious onset of symptoms and nonspecific clinical presentation contribute to delayed detection, with over 70% of cases diagnosed at an advanced, inoperable stage [2]. Consequently, the 5-year survival rate for metastatic GBC remains dismally low at less than 5%, underscoring the urgent need for improved diagnostic and therapeutic strategies [3].

This comprehensive review aims to consolidate contemporary knowledge on GBC, encompassing its epidemiological distribution, molecular pathogenesis, diagnostic modalities, staging systems, and multimodal treatment approaches. Furthermore, we critically evaluate emerging therapies, including immune checkpoint inhibitors and molecularly targeted agents, which hold promise for revolutionizing GBC management.

Epidemiology and Risk Factors

Global Incidence and Demographic Variations

GBC demonstrates striking geographical heterogeneity, with the highest age-standardized incidence rates (ASRs) observed in South America (particularly Chile and Bolivia), Northern India, Pakistan, and Eastern Europe [4]. Conversely, Western nations report significantly lower incidence rates, likely attributable to variations in genetic predisposition, dietary habits, and gallbladder pathology prevalence.

Table 1: Age-Standardized Incidence and Mortality Rates of Gallbladder Cancer (per 100,000 Population) [5]

Region	Male Incidence	Female Incidence	Male Mortality	Female Mortality
South America	4.2	12.8	3.8	11.2
Eastern Europe	3.5	7.1	3.2	6.5
Southeast Asia	2.9	8.6	2.7	8.1
North America	1.1	1.8	0.9	1.5

Established and Emerging Risk Factors

The pathogenesis of GBC is multifactorial, involving a complex interplay of environmental, genetic, and inflammatory factors:

- **Gallstones (Cholelithiasis):** Present in 70-90% of GBC cases, chronic gallstone disease induces persistent mucosal irritation and inflammation, fostering malignant transformation [6].
- **Chronic Inflammatory States:** Bacterial infections, notably Salmonella typhi and Helicobacter pylori, contribute to chronic cholecystitis and subsequent carcinogenesis [7].
- **Porcelain Gallbladder:** Diffuse mural calcification increases malignancy risk by 12-60%, necessitating prophylactic cholecystectomy in affected individuals [8].
- **Obesity and Metabolic Syndrome:** Hyperinsulinemia and adipokine dysregulation promote tumorigenesis through proliferative signaling pathways [9].
- **Genetic Susceptibility:** Germline mutations in BRCA1, BRCA2, and mismatch repair genes (Lynch syndrome) confer heightened GBC risk [10].

Molecular Pathogenesis and Genetic Alterations

GBC carcinogenesis follows a stepwise progression from metaplasia and dysplasia to invasive carcinoma, driven by cumulative genetic and epigenetic aberrations.

Key Genomic Alterations

Table 2: Recurrent Molecular Aberrations in Gallbladder Cancer [11]

Gene/Pathway	Alteration Frequency (%)	Functional Impact
TP53	50-70	Loss of tumor suppression
KRAS	10-30	Constitutive MAPK activation
ERBB2 (HER2)	10-20	Tyrosine kinase hyperactivity
CDKN2A	20-40	Cell cycle checkpoint disruption
PIK3CA	10-20	PI3K/AKT/mTOR pathway hyperactivation

Epigenetic Modifications

DNA hypermethylation of tumor suppressor genes (e.g., APC, RASSF1A) and dysregulation of oncogenic microRNAs (e.g., miR-21, miR-34a) further contribute to GBC progression [12].

Clinical Presentation and Diagnostic Evaluation

Symptomatology

- **Early-stage GBC:** Asymptomatic or incidentally detected during cholecystectomy for gallstone disease.
- **Locally Advanced Disease:**
  - Persistent right upper quadrant pain (50-70%)
  - Obstructive jaundice (30-50%) due to hepatic duct infiltration
  - Constitutional symptoms (weight loss, anorexia, fatigue)
  - Palpable gallbladder mass (Courvoisier's sign) [13]

Diagnostic Imaging Modalities

- **Abdominal Ultrasound (US):** Initial investigation for gallbladder wall thickening (>3 mm), polyps, or mass lesions.
- **Contrast-Enhanced Computed Tomography (CECT):** Assesses tumor extent, vascular invasion, and distant metastases.
- **Magnetic Resonance Imaging (MRI) / Magnetic Resonance Cholangiopancreatography (MRCP):** Superior soft-tissue delineation and biliary tree evaluation.
- **18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET):** Detects occult metastatic disease with 85-90% sensitivity [14].

Histopathological Classification

Table 3: World Health Organization (WHO) Histological Subtypes of Gallbladder Cancer [15]

Subtype	Frequency (%)	Key Characteristics
Adenocarcinoma	85-90	Glandular differentiation
Squamous cell carcinoma	2-5	Keratin pearl formation
Adenosquamous carcinoma	1-4	Mixed glandular/squamous features
Neuroendocrine carcinoma	<1	Small cell or large cell morphology

Staging And Prognostic Determinants

The American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) Staging System (8th Edition) is the gold standard for GBC classification [16].

Table 4: AJCC TNM Staging and Corresponding 5-Year Survival Rates [17]

Stage	Definition	5-Year Survival (%)
I	Tumor confined to mucosa (T1a) or muscularis (T1b)	50-80
II	Invasion beyond muscularis into perimuscular tissue	20-30
III	Hepatic invasion or regional lymph node metastasis	10-20
IV	Distant metastases (liver, peritoneum)	<5

Therapeutic Strategies

Surgical Interventions

- **Early-stage (T1a):** Laparoscopic cholecystectomy suffices.
- **T1b-T3:** Radical cholecystectomy with en bloc hepatic resection (segments IVb/V) and portal lymphadenectomy [18].

Systemic Therapy

- **Adjuvant Chemotherapy:** Gemcitabine-cisplatin (based on the PRODIGE-12 trial) or capecitabine (BILCAP trial) for resected disease [19].
- **Palliative Regimens:** FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) or gemcitabine-nab-paclitaxel for advanced GBC [20].

Radiotherapy

- **Neoadjuvant:** Role remains investigational.
- **Adjuvant:** Considered for node-positive or margin-positive cases.

Emerging Therapies

- **Immunotherapy:** Pembrolizumab (anti-PD-1) for microsatellite instability-high (MSI-H) tumors.
- **Targeted Agents:** Trastuzumab for HER2-amplified GBC; PARP inhibitors for BRCA-mutant cases.

Conclusion and Future Perspectives

Gallbladder carcinoma remains a formidable oncologic challenge with persistently poor outcomes despite medical advances. Its insidious onset and aggressive biology continue to frustrate clinicians, with most patients presenting at advanced, inoperable stages. The stark geographical disparities in incidence underscore the complex interplay of genetic, environmental, and socioeconomic factors influencing disease development and outcomes. While surgical resection offers the only curative potential, fewer than 30% of patients qualify for potentially curative operations at diagnosis.

The future of GBC management lies in three critical directions. First, enhanced early detection strategies through improved imaging protocols and biomarker development could transform outcomes by identifying premalignant lesions and early-stage tumors. Second, molecular characterization must guide therapeutic decisions, with HER2-targeted agents, immunotherapy for MSI-high tumors, and FGFR inhibitors showing particular promise. Third, international collaborative efforts are essential to overcome the challenges posed by this rare malignancy, facilitating large-scale clinical trials and data sharing.

Emerging technologies like liquid biopsies and artificial intelligence-assisted imaging analysis may revolutionize early diagnosis. Meanwhile, the growing understanding of tumor microenvironment interactions and immune evasion mechanisms opens new avenues for combination therapies. As precision medicine advances, the development of comprehensive molecular profiling protocols for all GBC patients will be crucial to identify targetable alterations and optimize treatment sequencing.

Ultimately, overcoming gallbladder cancer's dismal prognosis will require a concerted multidisciplinary approach integrating early detection, molecularly guided therapies, and global research collaboration. While significant challenges remain, these evolving strategies offer hope for meaningful progress against this deadly disease in the coming decade.

References

1. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014; 6:99-109.
2. Lazcano-Ponce EC, *et al.,* Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-64.
3. Ferlay J, *et al.,* Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. 2020.
4. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172-87.
5. Randi G, *et al.,* Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591-602.
6. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695-706.

7. Nath G, *et al.,* Association of Helicobacter pylori infection with gallbladder cancer. Indian J Gastroenterol. 2010;29(4):157-60.
8. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001;129(6):699-703.
9. Espinoza JA, *et al.,* The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016;1865(2):245-54.
10. Li M, *et al.,* Germline mutations in BRCA1 and BRCA2 in gallbladder cancer patients. Oncotarget. 2016;7(14):18094-102.
11. Roa JC, *et al.,* Molecular pathology of gallbladder cancer. Pathol Oncol Res. 2014;20(4):789-98.
12. Letelier P, *et al.,* DNA methylation profiling reveals novel biomarkers in gallbladder cancer. Epigenetics. 2017;12(6):418-26.
13. Misra S, *et al.,* Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167-76.
14. Rodríguez-Fernández A, *et al.,* FDG-PET in gallbladder cancer: diagnostic and prognostic utility. Eur J Nucl Med Mol Imaging. 2004;31(5):622-8.
15. Albores-Saavedra J, *et al.,* Tumours of the gallbladder and extrahepatic bile ducts. WHO Classification of Tumours. 2019; 7:266-74.
16. Amin MB, *et al.,* AJCC Cancer Staging Manual. 8th ed. Springer. 2017.
17. Henson DE, *et al.,* Survival analysis of gallbladder cancer based on tumor-node-metastasis staging. Cancer. 2001;92(5):1290-7.
18. Shih SP, *et al.,* Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg. 2007;245(6):893-901.
19. Primrose JN, *et al.,* Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized trial. Lancet Oncol. 2019;20(5):663-73.
20. Valle JW, *et al.,* Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81.